This article was originally published in Start Up
On the way to developing a neurostimulation device for delivering drugs across the blood grain barrier, BrainsGate has hit upon a novel acute stroke treatment that it hopes will extend the stroke treatment window to 24 hours and beyond.
You may also be interested in...
Rainbow Medical: Entrepreneurial Efficiency in Medical Devices
One of Israel's most prolific medical device entrepreneurs, Yossi Gross has launched an amazing number of companies in a wide array of clinical spaces. Two years ago, Gross and GlenRock Israel came up with the idea for Rainbow Medical, a new approach to creating companies around the technologies Gross develops. Rainbow is neither quite a venture fund nor a US-style incubator but has aspects of both. Rainbow's point: too many fledgling device companies have to spend their time raising money rather than developing their technology, while the founders have little experience in doing so or in building the company once capital comes in. Rainbow's innovative investment-fund strategy addresses both issues.
Neurostimulation Market Expanding
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
US Markets for Neurostimulation Products
According to "US Markets for Neurostimulation Products," a report published in November 2006 by the Medtech Insight division of Windhover Information Inc., neurostimulation devices have the potential to address several clinical applications in which patient populations number in the millions: chronic pain affects five million people in the US; chronic depression four million, and chronic migraine headache two million. Based on projects currently in development, Medtech Insight lists 18 separate clinical indications for neurostimulation, from Alzheimer's disease to sleep apnea.